Pharmacokinetics of zidovudine in cats

American Journal of Veterinary Research

Volumn 65, Issue 6, 2004, Pages 835-840

  Zhang, Weijiang ^a,b   Mauldin, Jeffrey K ^a,c   Schmiedt, Chad W ^a,d   Brockus, Charles W ^a,e   Boudinot, F Douglas ^a,f   McCrackin Stevenson, M A ^a,g  

^a UNIVERSITY OF GEORGIA   (United States)

^b TAP PHARMACEUTICAL PRODUCTS INC   (United States)

^c Culbreth Carr Watson Animal Clinic   (United States)

^d UNIVERSITY OF WISCONSIN MADISON   (United States)

^e IOWA STATE UNIVERSITY   (United States)

^f VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^g Valley Pet Clinic   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ADEFOVIR; ANTI HUMAN IMMUNODEFICIENCY VIRUS AGENT; ANTIRETROVIRUS AGENT; DIDANOSINE; DRUG METABOLITE; LAMIVUDINE; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ANIMAL EXPERIMENT; ANXIETY; AREA UNDER THE CURVE; ARTICLE; BONE MARROW SUPPRESSION; CAT; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE TIME EFFECT RELATION; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CAPSULE; DRUG CLEARANCE; DRUG ELIMINATION; DRUG GLUCURONIDATION; DRUG HALF LIFE; DRUG METABOLISM; DRUG SOLUTION; FELINE IMMUNODEFICIENCY VIRUS; FEMALE; HEMOLYSIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; MALE; NONHUMAN; RESTLESSNESS; SINGLE DRUG DOSE; STATISTICAL SIGNIFICANCE; STEADY STATE; SUSPENSION; VIRUS INHIBITION; VIRUS ISOLATION; VIRUS REPLICATION;

ADMINISTRATION, ORAL; ANIMALS; AREA UNDER CURVE; BIOLOGICAL AVAILABILITY; CATS; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CROSS-OVER STUDIES; INJECTIONS, INTRAVENOUS; REVERSE TRANSCRIPTASE INHIBITORS; TIME FACTORS; ZIDOVUDINE;

ANIMALIA; FELIDAE; FELINE IMMUNODEFICIENCY VIRUS; FELIS CATUS; HUMAN IMMUNODEFICIENCY VIRUS;

EID: 3042674187     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.2004.65.835     Document Type: Article

References (51)

1. Pedersen NC, Ho EW, Brown ML, et al. Isolation of a T-lymphotropic virus from domestic cats with an immunodeficiency-like syndrome. Science 1987;235:790-793.
2. North TW, North GL, Pedersen NC. Feline immunodeficiency virus, a model for reverse transcriptase-targeted chemotherapy for acquired immune deficiency syndrome. Antimicrob Agents Chemother 1989;33:915-919.
3. Pedersen NC, Barlough JE. Clinical overview of feline immunodeficiency virus. J Am Vet Med Assoc 1991;199:1298-1305.
4. Physicians' desk reference. 57th ed. Montvale, NJ: Medical Economics Co, 2003;1625.
5. Egberink H, Borst M, Niphuis H, et al. Suppression of feline immunodeficiency virus infection in vivo by 9-(2-phosphonomethoxyethyl)adenine. Proc Natl Acad Sci USA 1990;87:3087-3091.
6. McCrackin Stevenson MA, McBroom DG. In vitro characterization of FIV-pPPR, a pathogenic molecular clone of feline immunodeficiency virus, and two drug-resistant pol gene mutants. Am J Vet Res 2001;62:588-594.
7. Smyth NR, Bennett M, Gaskell RM, et al. Effect of 3′azido-2′,3′-deoxythymidine (AZT) on experimental feline immunodeficiency virus infection in domestic cats. Res Vet Sci 1994;57:220-224.
8. Hartmann K, Ferk G, North TW, et al. Toxicity associated with high dosage 9-[(2R,5R-2,5-dihydro-5-phosphonomethoxy)-2-furanyl]adenine therapy and attempts to abort early FIV infection. Antiviral Res 1997;36:11-25.
9. Vahlenkamp TW, de Ronde A, Balzarini J, et al. (R)-9-(2-phosphonylmethoxypropyl)-2,6-diaminopurine is a potent inhibitor of feline immunodeficiency virus infection. Antimicrob Agents Chemother 1995;39:746-749.
10. Egberink HF, Hartman K, Horzinek MC. Chemotherapy of feline immunodeficiency virus infection. J Am Vet Med Assoc 1991;199:1485-1487.
11. Hartmann K, Donath A, Beer B, et al. Use of two virustatica (AZT, PMEA) in the treatment of FIV and of FeLV seropositive cats with clinical symptoms. Vet Immunol Immunopathol 1992;35:167-175.
12. Hart S, Nolte I. Long-term treatment of diseased, FIV-seropositive field cats with azidothymidine (AZT). Zentralbl Veterinarmed [A] 1995;42:397-409.
13. Hayes KA, Wilkinson JG, Frick R, et al. Early suppression of viremia by ZDV does not alter the spread of feline immunodeficiency virus infection in cats. J Acquir Immune Defic Syndr Hum Retrovirol 1995; 9:114-122.
14. Gregory CR, Barlough JE, Clark R, et al. Effects of insulin-like growth factor-1 and AZT in cats experimentally infected with FIV. Feline Pract 1997;25(N4):23-31.
15. Arai M, Earl DD, Yamamoto JK. Is AZT/3TC therapy effective against FIV infection or immunopathogenesis? Vet Immunol Immunopathol 2002;85:189-204.
16. Tavares L, Roneker C, Johnston K, et al. 3′-Azido-3′-deoxythymidine in feline leukemia virus-infected cats: a model for therapy and prophylaxis of AIDS. Cancer Res 1987; 47:3190-3194.
17. Haschek WM, Weigel RM, Scherba G, et al. Zidovudine toxicity in cats infected with feline-leukemia virus. Fundam Appl Toxicol 1990; 14:764-775.
18. Zeidner NS, Myles MH, Mathiason-DuBard CK, et al. Alpha interferon (2b) in combination with zidovudine for the treatment of presymptomatic feline leukemia virus-induced immunodeficiency syndrome. Antimicrob Agents Chemother 1990;34:1749-1756.
19. Mathes LE, Polas PJ, Hayes KA, et al. Pre- and postexposure chemoprophylaxis: evidence that 3′-azido-3′-dideoxythymidine inhibits feline leukemia virus disease by a drug-induced vaccine response. Antimicrob Agents Chemother 1992;36:2715-2721.
20. Jordan HL, Pereira AS, Cohen MS, et al. Domestic cat model for predicting human nucleoside analogue pharmacokinetics in blood and seminal plasma. Antimicrob Agents Chemother 2001;45:2173-2176.
21. Hartmann K, Donath A, Kraft W. AZT in the treatment of feline immunodeficiency virus infection. Part 1. Feline Pract 1995; 23(5):16-21.
22. Hartmann K, Donath A, Kraft W. AZT in the treatment of feline immunodeficiency virus infection. Part 2. Feline Pract 1995; 23(6):13-20.
23. Doshi KJ, Gallo JM, Boudinot FD, et al. Comparative pharmacokinetics of 3′-azido-3′-deoxythymidine (AZT) and 3′-azido-2′,3′-dideoxyuridine (AZddU) in mice. Drug Metab Dispos 1989;17:590-594.
24. Mays DC, Dixon KF, Balboa A, et al. A nonprimate animal model applicable to zidovudine pharmacokinetics in humans: inhibition of glucuronidation and renal excretion of zidovudine by probenecid in rats. J Pharmacol Exp Ther 1991;259:1261-1270.
25. Boudinot FD, Schinazi RF, Gallo JM, et al. 3′-Azido-2′,3′-dideoxyuridine (AzddU): comparative pharmacokinetics with 3′-azido-3′-deoxythymidine (AZT) in monkeys. AIDS Res Hum Retroviruses 1990; 6:219-228.
26. Klecker RW Jr, Collins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′ -deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS and related diseases. Clin Pharmacol Ther 1987;41:407-412.
27. Zidovudine. In: Dollery C, ed. Therapeutic drugs. Edinburgh: Churchill Livingstone, 1999;Z12-Z18.
28. Stevenson MA, Stiffler KS, Schmiedt CW. One-step placement of a percutaneous nonendoscopic low-profile gastrostomy port in cats. J Am Vet Med Assoc 2000;217:1636-1641.
29. Patel BA, Boudinot FD, Schinazi RF, et al. Comparative pharmacokinetics and interspecies scaling of 3′-azido-3′-deoxy-thymidine (AZT) in several mammalian species. J Pharmacobiodyn 1990; 13:206-211.
30. Manouilov KK, Fedorov II, Boudinot FD, et al. Lymphatic targeting of anti-HIV nucleosides: distribution of 3′-azido-3′-deoxythymidine (AZT) and 3′-azido-2′,3′-dideoxyuridine (AZdU) after administration of dipalmitoylphosphatidyl prodrugs to mice. Antivir Chem Chemother 1995;6:230-238.
31. Tyler RD, Cowell RL, Meinkoth JH. Bone marrow. In: Cowell RL, Tyler RD, Mainkoth JH, eds. Diagnostic cytology and hematology of the dog and cat. 2nd ed. St Louis: CV Mosby Co, 1999;284-304.
32. Wilcke JR. Principles of drug therapy. In: Sherding RG, ed. The cat: diseases and clinical management. New York: Churchill Livingstone Inc, 1989;23-34.
33. Zhang W, Mauldin JK, Schmiedt CW, et al. Pharmacokinetics of lamivudine (3TC) in cats. Am J Vet Res 2004;65:xxx-xxx.
34. Physicians' desk reference. 57th ed. Montvale, NJ: Medical Economics Co, 2003;1508.
35. Grindem CB, Corbett WT, Ammerman BE, et al. Seroepidemiologic survey of feline immunodeficiency virus infection in cats of Wake County, North Carolina. J Am Vet Med Assoc 1989; 194:226-228.
36. Hopper CD, Cripps PJ, Howard PE, et al. The epidemiology of feline immunodeficiency virus infection in cats in the United Kingdom, in Proceedings. Soc Vet Epidemiol Prev Med 1991;67-74.
37. Hosie MJ, Robertson C, Jarrett O. Prevalence of feline leukaemia virus and antibodies to feline immunodeficiency virus in cats in the United Kingdom. Vet Rec 1989;125:293-297.
38. Ishida T, Washizu T, Toriyabe K, et al. Detection of feline T-lymphotropic lentivirus (FTLV) infection in Japanese domestic cats. Nippon Juigaku Zasshi 1988;50:39-44.
39. O'Connor TP Jr, Tonelli QJ, Scarlett JM. Report of the National FeLV/FIV Awareness Project. J Am Vet Med Assoc 1991; 199:1348-1353.
40. Shelton GH, Waltier RM, Connor SC, et al. Prevalence of feline immunodeficiency virus and feline leukemia virus infections in pet cats. J Am Anim Hosp Assoc 1989;25:7-12.
41. Yamamoto JK, Hansen H, Ho EW, et al. Epidemiologic and clinical aspects of feline immunodeficiency virus infection in cats from the continental United States and Canada and possible mode of transmission. J Am Vet Med Assoc 1989;194:213-220.
42. AVMA. Feline practitioners recommend new FIV and FeLV testing guidelines, initiate public awareness campaign. J Am Vet Med Assoc 2001;218:1247.
43. Lee IT, Levy JK, Gorman SP, et al. Prevalence of feline leukemia virus infection and serum antibodies against feline immunodeficiency virus in unowned free-roaming cats. J Am Vet Med Assoc 2002; 220:620-622.
44. Pu R, Coleman J, Omori M, et al. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates. AIDS 2001;15:1225-1237.
45. Lee T, Laco GS, Torbett BE, et al. Analysis of the S3 and S3′ subsite specificities of feline immunodeficiency virus (FIV) protease: development of a broad-based protease inhibitor efficacious against FIV, SIV, and HIV in vitro and ex vivo. Proc Natl Acad Sci U S A 1998; 95:939-944.
46. Uckun FM, Chen CL, Samuel P, et al. In vivo antiretroviral activity of stampidine in chronically feline immunodeficiency virus-infected cats. Antimicrob Agents Chemother 2003;47:1233-1240.
47. Levy JK. Antiviral therapy of FeLV and FIV, in Proceedings. 14th Annu Meet North Am Vet Conf Small Anim 2000;382-384.
48. Levy JK. Emerging disease syndromes in FeLV- and FIV-infected cats, in Proceedings. 14th Annu Meet North Am Vet Conf Small Anim 2000;379-381.
49. Smyth NR, Bennett M, Gaskell RM, et al. Effect of 3′azido-2′,3′-deoxythymidine (AZT) on experimental feline immunodeficiency virus infection in domestic cats. Res Vet Sci 1994; 57:220-224.
50. Hayes KA, Lafrado LJ, Erickson JG, et al. Prophylactic ZDV therapy prevents early viremia and lymphocyte decline but not primary infection in feline immunodeficiency virus-inoculated cats. J Acquir Immune Defic Syndr 1993;6:127-134.
51. Meers J, del Fierro GM, Cope RB, et al. Feline immunodeficiency virus infection: plasma, but not peripheral blood mononuclear cell virus titer is influenced by zidovudine and cyclosporine. Arch Virol 1993;132:67-81.